ClinicalTrials.gov
public full text
Public Domain
A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors
This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-428 when administered as monotherapy or in combination with nivolumab in participants with advanced solid tumors.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- SKB445 for Injection in Solid Tumors#1096182
- A Study of EMD525797 in Solid Tumor Patients in Japan#861168
- A Study of ABT-806 in Subjects With Advanced Solid Tumor Types#839426
- An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors#850016
- A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors#910014
Record · ID 875330
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive